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Production of omega-3 long chain polyunsaturated fatty acids
Field of the Invention
The present invention relates to a recombinant oilseed plant or cell for producing
omega-3 long chain polyunsaturated fatty acids such as eicospentaenoic acid (EPA)
and docosahexaenoic acid (DHA). The invention further relates to the oil produced
by said recombinant oilseed plant or cell.
Background to the Invention
Two main families of poly-unsaturated fatty acids are the omega-3 fatty acids,
exemplified by EPA, and the omega-6 fatty acids, exemplified by arachidonic acid
(Figure 1).
The starting material for the omega-6 metabolic pathway is the fatty acid linoleic acid
while the omega-3 pathway proceeds via linolenic acid. Linolenic acid is formed by
the activity of an omega-3 desaturase (Tocher et al. 1998, Prog. Lipid Res. 37, 73-
117 ; Domergue et al. 2002, Eur. J. Biochem. 269, 4105-41 13).
Omega-3 highly unsaturated fatty acids are recognized as being important dietary
compounds for preventing arteriosclerosis and coronary heart disease, for alleviating
inflammatory conditions and for retarding the growth of tumor cells. These beneficial
effects are a result both of omega-3 highly unsaturated fatty acids causing
competitive inhibition of compounds produced from omega-6 fatty acids, and from
beneficial compounds produced directly from the omega-3 highly unsaturated fatty
acids themselves (Simopoulos et al. (1986) Health Effects of Polyunsaturated Fatty
Acids in Seafoods, Academic Press, New York).
Omega-3 long chain polyunsaturated fatty acids are crucial to brain development
and normal brain functioning (Neuringer, et al., (1988) Annu Rev Nutr 8 , 517-541)
with DHA particularly important to brain functioning due to its influence on neural
membrane properties, which modulate cell signalling (Uauy, R., and Dangour, A. D.
(2006) Nutr Rev 64, S24-33; discussion S72-91). DHA concentration in the brain
decreases with age in humans, something that has been postulated to be
consequential to the age-related deterioration in central nervous system functions
(Soderberg et al. (1991) Lipids 26, 421-425). Evidence from animal studies supports
this, with animals fed a low omega-3 long chain polyunsaturated fatty acid diet
showing cognitive deficits (Suzuki et al. ( 1998) Mech Ageing Dev 10 1, 119-1 28) that
are ameliorated by DHA supplementation (Moriguchi, T., and Salem, N., Jr. (2003) J
Neurochem 87, 297-309; Chung, et al. (2008) J Nutr 138, 165-1 171).
In humans, it has been consistently reported that a higher intake offish is related to
reduced cognitive decline (van Gelder et al. (2007) Am J Clin Nutr 85, 1142-1 147;
Kalmijn et al. (1997) Ann Neurol 42, 776-782; Morris et al. (2005) Arch Neurol 62,
1849-1853; Kalmijn et al. (1997) Am J Epidemiol 145, 33-41) and incidence of
dementia (Kalmijn et al. (1997) Ann Neurol 42, 776-782), and associated with better
cognitive performance (Morris et al., (2005) Arch Neurol 62, 1849-1853; Kalmijn et
al. (2004) Neurology 62, 275-280; Nurk et al. (2007) Am J Clin Nutr 86, 1470-1478;
Dangour et al. (2009) J Nutr Health Aging 13, 198-202). Significant positive
relationships between cognitive outcomes and dietary intake levels of omega-3 long
chain polyunsaturated fatty acids have also been established (van Gelder et al.
(2007) Am J Clin Nutr 85, 1142-1 147; Morris et al. (2003) Arch Neurol 60, 940-946;
Kalmijn et al. (2004) Neurology 62, 275-280). These positive relationships are
further strengthened if one considers the plasma or erythrocyte level/status of
omega-3 long chain polyunsaturated fatty acids. Here, DHA/EPA levels have been
associated with better cognitive function in normal older adult (Whalley et al. (2004)
Am J Clin Nutr 80, 1650-1657; Whalley et a . (2008) Am J Clin Nutr 87, 449-454),
better cognitive outcomes over time (Whalley et al. (2008) Am J Clin Nutr 87, 449-
454), and reduced risk of cognitive decline (Heude et al. (2003) Am J Clin Nutr 77,
803-808) and a lower risk of developing dementia (Schaefer et al. (2006) Arch
Neurol 63, 1545-1550).
Studies in cognitively healthy populations have failed to show efficacy in improving
cognition (Dangour et al. (2010) Am J Clin Nutr 91, 1725-1732; van de Rest et al.
(2008) Neurology 71, 430-438). However, omega-3 long chain polyunsaturated fatty
acid supplementation has been shown to be efficacious in cognitively impaired
individuals (primarily mild cognitively impaired; MCI), where interventions had a
beneficial effect on cognitive outcomes (Chiu et al. (2008) Prog
Neuropsychopharmacol Biol Psychiatry 32, 1538-1544; Freund-Levi et al. (2006)
Arch Neurol 63, 1402-1408; Yurko-Mauro et al. (2010) Alzheimers Dement 6 , 456-
464). Furthermore, they have been shown to be beneficial in at risk AD individuals
carrying the apolipoprotein E (ApoE) ε4 allele, with these individuals showing an
improvement in sustained attention after 26 weeks intervention with both low (226
mg EPA, 176 mg DHA) and high (1093 mg EPA, 847 mg DHA) doses offish oil.
Bacteria and yeast are not known to synthesize omega-3 highly unsaturated fatty
acids and only a few fungi are known which can produce minor and trace amounts of
omega-3 highly unsaturated fatty acids (Weete (1980) Lipid Biochemistry of Fungi
and Other Organism. Plenum Press, New York; Wassef, M. (1977) "Fungal lipids."
Adv. Lipid Res.).
Currently the primary dietary source of omega-3 highly unsaturated fatty acids is from
certain fish oils which can contain up to 20-30% of these fatty acids in their
triacylglycerides. Consequently large quantities of fish oil are processed and
encapsulated each year for sale as a dietary supplement.
However, fish stocks may undergo natural fluctuations or may be depleted by
overfishing. Furthermore, fish oils, can accumulate environmental pollutants and may
contain high levels of fat-soluble vitamins that are found naturally in fish oils. When
ingested, these vitamins are stored and metabolized in fat in the human body rather
than excreted in urine. Additionally, fish oils have an unpleasant taste and odour
when they undergo oxidation, and as such cannot be added to processed foods as a
food additive, without impairing the taste of the food product. Moreover, the refining
of pure omega-3 highly unsaturated fatty acids from crude extracts of fish oils is an
involved and expensive process resulting in very high prices for pure forms of these
fatty acids.
The primary natural source of omega-3 unsaturated fatty acids in fish oil is in fact
marine unicellular microbes such as algae and diatoms, at the base of the aquatic
foodweb. These highly unsaturated fatty acids are important components of
photosynthetic membranes. Omega-3 highly unsaturated fatty acids accumulate in
the food chain and are eventually incorporated into fish oils.
Owing to the positive characteristics of omega-3 polyunsaturated fatty acids, genes
have been identified which are involved in the biosynthesis of these fatty acids in a
variety of organisms.
Linoleic acid (LA, 18:2 '12) is converted to a-linolenic acid (ALA, 18:3 · '15) the first
of the omega-3 fatty acids, by the action of a ∆ 15 desaturase. Subsequently, ALA is
converted to stearodonic acid (SDA, 8:4 '9,12,15) by the activity of a ∆6 desaturase;
SDA is converted to eicosatetraenoic acid (ETA, 20:4 ∆8,11,14,17) by the activity of an
elongase; and ETA is converted to eicosapentaenoic acid (EPA, 20:5 , '11,14,17) by
the activity of a ∆5 desaturase. Alternatively, ETA and EPA can be produced from di-
homo γ-linolenic acid (DGLA, 20:3 '11 4) and arachidonic acid (ARA, 20:4 '8·1 1 4)
respectively, by the activity of a ∆ 17 desaturase. EPA can be further converted to
DHA by the activity of an elongase and a ∆4 desaturase (see Figure 1).
While higher plants comprise polyunsaturated fatty acids such as linoleic acid and
linolenic acid, long-chain polyunsaturated fatty acids such as DHA and EPA are not
found at all in the seed oil of such plants, or only in miniscule, nutritionally-irrelevant
amounts. The production of long-chain polyunsaturated fatty acids, in particular
omega-3 fatty acids, in higher plants would be advantageous since large amounts of
high-quality long-chain polyunsaturated fatty acids (and associated triacylglycerides)
for the food industry, animal nutrition and pharmaceutical purposes might be
obtained economically.
Transgenic linseed oil plants have been shown to result in the accumulation of high
levels of ∆6 desaturatesd C 8 fatty acids. However, only very low levels of C2
polyunsaturated fatty acids have been obtained. The synthesis and accumulation of
omega-3 LC-PUFAs such as EPA and DHA in the seeds of transgenic plants has
previously reported in the literature but with limited success and unpredictable
results.
Abbadi et al. (Plant Cell. 2004 Oct;16(10):2734-48. Epub 2004 Sep 17) described
attempts to produce EPA in the seeds of transgenic linseed, using a three-gene
construct containing a ∆6-desaturase (D6D) from Phaeodactylum tricornutum
(AY082393), A6-elongase (D6E) from Physcomitrella patens (AF428243) and ∆5-
desaturase (D5D) from Phaeodactylum tricornutum (AY082392). Linseed was
chosen as a host species for the seed-specific expression of these genes on account
of the very high levels of endogenous substrate (ALA) for prospective conversion to
EPA. However, despite the presence of almost 50% ALA in the seeds of developing
linseed, less than 1% EPA (0.8% of total fatty acids) was generated. In addition, very
high levels of the undesired biosynthetic intermediate the omega-6 fatty acid y-
linolenic acid (GLA) were reported (16.8% of total fatty acids). This simultaneous
accumulation of high levels of GLA and low synthesis of EPA was ascribed by
Abbadi et al. (Plant Cell. 2004 Oct;16(10):2734-48. Epub 2004 Sep 17) to the
phospholipid-dependent substrate-requirements of the D6D.
Similar results were also reported by W u et al. (Nat Biotechnol, 2005, 23:1013-7)
who described the seed-specific expression of a 3 gene construct (D6D from Pythium
irregulare, CAJ30866; D6E from Physcomitrella patens; D5D from Thraustochytrium,
AX467713) in Brassica juncea, yielding 0.8% EPA but 27.7% of the undesirable
omega-6 GLA. More complex gene constructs were also reported by Wu et al. in
which they attempted to boost the accumulation of EPA in transgenic B. juncea. A
four gene construct comprising the same D6D, D6E, D5D activities and additionally
the FAD2 A12-desaturase from Calendula officinalis (AF343065) resulted in a small
increase in EPA to 1.2% but also a concomitant increase in GLA to 29.4%. A five
gene construct, comprising D6D, D6E, D5D, FAD2 and a second ∆δ-elongase
D6E#2 from Thraustochytrium (AX214454) had equally marginal impact on the fatty
acid composition of the seeds of transgenic B. juncea, yielding 1.4% EPA and 28.6%
GLA. A six gene construct, comprising the same D6D, D6E, D5D, FAD2, D6E#2 and
a w3-desaturase w3D from Phytophthora infestans (CS160901), yielded the best
levels of EPA at 8.1% - however, the levels of GLA remained high at 27.1%. In a
further iteration, W u et al. (Nat Biotechnol, 2005, 23:1013-7) also attempted to
engineer the accumulation of both EPA and DHA, through the seed-specific
expression of nine genes (D6D, D6E, D5D, FAD2, D6E#2, w3D, and additionally a
A5-elongase (D5E) from fish (Oncorhynchus mykiss; CS020097), a A4-desaturase
(D4D) from Thraustochytrium (AF489589), and an acyltransferase also from the
same organism). This yielded B. juncea seeds containing on average 8.1% EPA and
0.2% DHA. Again, GLA levels remained markedly higher (27.3%). W u et al. reported
a maximal level of EPA observed in transgenic B. juncea as 15% and a maximal
DHA level of 1.5% (based on individual plants for their nine gene construct.
Similar experiments were carried out in the model oilseed species Arabidopsis
thaliana: Robert et al. (Functional Plant Biol, 2005, 32: 473-479) reported the low
level accumulation of EPA (3.2% of total fatty acids) in the seeds of Arabidopsis on
the expression of two genes, a Afunctional D6D/D5D from zebrafish (Danio rerio,
AF309556) and a D6E from the nematode Caenhorabditis elegans (Z68749).
Interestingly, this construct also showed significantly reduced accumulation of GLA, a
fact that Robert et al. attributed to the acyl-CoA-dependent substrate requirement of
the D6D/D5D. Further transformation of this EPA-accumulating Arabidopsis iine with
genes for DHA synthesis (D4D and D5E from Pavlova salina, AY926605, AY926606)
resulted in a mean level of 0.3% DHA, again with basal levels of the unwanted co-
product GLA (0.3%).
Very similar results were reported by Hoffmann et al. (J Biol Chem, 2008, 283:22352-
62) who postulated that the use of an "acyl-CoA-dependent" pathway in transgenic
plants would decrease the build-up of biosynthetic intermediates such as GI_A whilst
simultaneously increase the accumulation of EPA. However, the seed-specific
expression in Arabidopsis of acyl-CoA-dependent D6D and D5D activities from
Mantoniella squamata (AM949597, AM949596) (in conjunction with the previously
described D6E from P. patens) yielded barely detectable levels of EPA (<0.1% of
total seed fatty acids and < 0.05% GLA. Analogous data have been reported by
Ruiz-Lopez et al. (Transgenic Res. 2012 (doi:10.1007/s1 1248-012-9596-0)) who
expressed a number of different gene combinations in Arabidopsis. Notably, a six
gene construct comprising a D6D from Pythium irregulare, (CAJ30866); D6E from
Physcomitrella patens (AF428243); D5D from Thraustochytrium, (AX467713); a
bifunctional D12/15 desaturase from Acanthamoeba castellanii, EF017656; w3D from
Phytophthora infestans (CS 160901) and a second D6E from Thalassiosira
pseudonana, (AY591337) yielded 2.5% EPA of total seed fatty acids with the
concomitant accumulation of 13.3% GLA. In contrast, a four gene construct that
contained an acyl-CoA-dependent D6D from Ostreococcus tauri (AY746357), D6E
from Thalassiosira pseudonana (AY591337), D5D from Thraustochytrium,
(AX467713) and FAD2 from Phytophtora sojae (CS423998) generated low levels of
both EPA (2% of total fatty acids) and GLA ( 1 .0%).
More recently, Cheng et al. (Transgenic Res, 2010, 19:221-9) reported the
accumulation of EPA in transgenic Brassica carinata. For example, the seed-specific
expression of 3 genes (D6D from Pythium irregulare, CAJ30866; D6E from
Thalassiosira pseudonana, AY591337; D5D from Thraustochytrium, AX467713)
resulted in a mean level of 2.3% EPA, with high level co-accumulation of GLA
(17.6%). A four gene construct (D6D, D6E, D5D and w3D from Claviceps purpurea,
EF536898) resulted in 4.2% EPA and 11.8% GLA, whilst a five gene construct (D6D,
D6E, D5D, w3D and an additional w3-desaturase from Pythium irregular,
(FB753541 )) yielded 9.7% EPA and 11.1% GLA. Such levels are very similar to that
observed with five and six gene constructs in B. juncea (Wu et al. 2005, Nat
Biotechnol, 2005, 23:1013-7). Cheng et al. introduced a different 5 gene construct
(D6D from Pythium irregulare, CAJ30866; D6E from Thraustochytrium, HC476134;
D5D from Thraustochytrium, AX467713; FAD2 from Calendula officinalis, AF343065
and w3D from Pythium irregulare, FB753541) into two different cultivars of B.
carinata, differing in their accumulation of the C22 monounsaturated fatty acid erucic
acid. Expression of this construct in conventional high erucic acid B. carinata
resulted again in a mean accumulation of 9.3% EPA and 18.2% GLA. Expression in
the zero-erucic acid genotype yielded an increase in EPA though this genotype also
resulted in the co-accumulation of high levels of GLA (26.9%).
The present invention addresses the need for systems that produce commercially
useful levels of omega-3 highly unsaturated fatty acids in the seeds of terrestrial
plants.
Summary of the Invention
Camelina sativa is a genus within the flowering plant family Brassicaceae. Camelina
is a short season crop, and has gained notoriety for its ability to withstand water
shortages in early stages of development. In recent years, there has been increasing
interest in the use of camelina oil as a biofuel and bio-lubricant, mainly in view of this
crop's low nitrogen requirements.
The present invention relates to the surprising finding that camelina can be
transformed with desaturase and elongase enzymes to produce omega-3 fatty acids.
Indeed, following the introduction of these enzymes into camelina, it is not only
possible to generate omega-3 fatty acids, but it is possible to create novel oil
compositions.
According to a first aspect of the present invention there is provided a recombinant
camelina plant or cell comprising one or more polynucleotides encoding a ∆6-
desaturase, a ∆δ-elongase and a A5-desaturase operably linked with one or more
regulatory sequences.
Thus, there is provided a camelina plant or cell transformed with genes encoding a
∆ -desaturase, a A6-elongase and a ∆δ-desaturase.
The ∆δ-desaturase, ∆δ-elongase and ∆δ-desaturase enzymes can be encoded by a
single or separate polynucleotide(s). What is important is that the recombinant
camelina plant or host according to the first aspect of the invention comprises
polynucleotide sequences for all three enzymes.
In a preferred embodiment of the first aspect of the invention, the recombinant
camelina plant or cell is produced by transforming a camelina plant or cell with a
polynucleotide encoding a ∆ -desaturase, a ∆ -elongase and a A5-desaturase
operably linked with one or more regulatory sequences.
Alternatively, the recombinant camelina plant or cell may be produced by
transforming a camelina plant or cell with separate polynucleotides each encoding a
∆β-desaturase and/or a ∆β-elongase and/or aA5-desaturase.
The recombinant camelina plant or cell of this aspect of the invention may further
comprise one or more polynucleotides encoding a A12-desaturase and/or a 3
desaturase operably linked with one or more regulatory sequences. Thus, there is
provided a recombinant camelina plant or cell comprising one or more
polynucleotides encoding a ∆ -desaturase, a ∆ -elongase, aA5-desaturase, a ∆ 12-
desaturase and 3 desaturase operably linked to one or more regulatory elements.
In a preferred embodiment, the recombinant camelina plant or cell is produced by
transforming a camelina plant or cell with a polynucleotide encoding a ∆6-
desaturase, a ∆6-elongase, a ∆ 5-desaturase, a A12-desaturase and a 3
desaturase operably linked with one or more regulatory sequences.
According to a second aspect of the present invention there is provided a method for
producing eicosapentaenoic acid (EPA) comprising growing a plant or cell according
to the first aspect of the invention under conditions wherein said desaturase and
elongase enzymes are expressed and EPA is produced in said plant or cell.
According to third aspect of the present invention there is provided a method for
producing a plant seed oil comprising growing a recombinant camelina plant or cell of
the first aspect of the invention whereby said desaturase and elongase enzymes are
expressed and oil is produced in said plant or cell.
According to fourth aspect of the present invention there is provided a plant seed oil
produced by the recombinant camelina plant or cell of the first aspect of the present
invention.
According to a fifth aspect of the present invention there is provided a plant seed oil
wherein EPA constitutes at least 5%, at least 10%, at least 20%, at least 25% or at
least 30% (mol %) of the total of the total amount of fatty acid present in said oil.
Said oil may be produced by a recombinant camelina plant or cell of the first aspect
of the present invention.
In one embodiment, the EPA constitutes at least 15, 20, 25 or 30% (mol %) of the
total fatty acid content of said oil, and the γ-linolenic (GLA) constitutes less than 10%
(mol %) of the total fatty acid content of said oil.
In one embodiment, the EPA constitutes 20% to 35%, preferably 20 to 31% (mol %)
of the total fatty acid content of said oil.
The GLA may constitute less than 7% (mol %) of the total fatty acid content of said
oil. In one embodiment, the GLA constitutes 1% to 6% (mol %) of the total fatty acid
content of said oil.
The ratio of the molar percentages of EPA to γ-linolenic (GLA) may be, for example,
about 3:1 to about 22:1, preferably about 5:1 to about 20:1, preferably about 8:1 to
about 20:1.
According to a sixth aspect of the present invention there is provided a recombinant
camelina plant or cell comprising one or more polynucleotides encoding a ∆6-
desaturase, a ∆ -elongase, a ∆ -desaturase, a ∆ -elongase and a A4-desaturase
operably linked with one or more regulatory sequences.
Thus, there is provided a camelina plant or cell transformed with genes encoding a
∆β-desaturase, a ∆ -elongase, a ∆ -desaturase, a ∆ -elongase and a ∆4-
desaturase.
The A6-desaturase, ∆β-elongase, ∆ -desaturase, ∆ -elongase and A4-desaturase
can be encoded by a single or separate polynucleotide(s). What is essential is that
the recombinant camelina plant or cell according to the sixth aspect of the invention
comprises polynucleotide sequences for all five enzymes.
Preferably, the recombinant camelina plant or cell according to this aspect of the
invention is produced by transforming a camelina plant or cell with a polynucleotide
encoding a A6-desaturase, a A6-elongase, a A5-desaturase, a ∆ -elongase and a
A4-desaturase operably linked with one or more regulatory sequences.
Alternatively, the recombinant camelina plant or cell may be produced by
transforming a camelina plant or cell with separate polynucleotides each encoding a
∆ -desaturase, and/or ∆δ-elongase, and/or ∆ -desaturase, and/or ∆δ-elongase
and/or a A4-desaturase.
The recombinant camelina plant or cell of this aspect of the invention may further
comprise one or more polynucleotides encoding a ∆ 2-desaturase and/or a ω3
desaturase operably linked with one or more regulatory sequences. Thus, there is
provided a recombinant camelina plant or cell comprising one or more
polynucleotides encoding a ∆ -desaturase, a ∆ -elongase, a A5-desaturase, a ∆ 12-
desaturase, a ∆δ-elongase, a A4-desaturase and a 3 desaturase operably linked to
one or more regulatory elements. In a preferred embodiment, the recombinant
camelina plant or cell is produced by transforming a camelina plant or cell with a
polynucleotide encoding a A6-desaturase, a ∆ -elongase, a ∆ -desaturase, a ∆5-
elongase, a A4-desaturase, a A12-desaturase and a 3 desaturase operably linked
with one or more regulatory sequences.
According to a seventh aspect of the present invention there is provided a method for
producing docosahexaenoic acid (DHA) and/or EPA comprising growing a plant or
cell according to the sixth aspect of the invention under conditions wherein said
desaturase and elongase enzymes are expressed and DHA and/or EPA is produced
in said plant or cell.
According to eighth aspect of the present invention there is provided a method for
producing a plant seed oil comprising growing a recombinant camelina plant or cell of
the sixth aspect of the invention whereby said desaturase and elongase enzymes are
expressed and oil is produced in said plant or cell.
According to a ninth aspect of the present invention there is provided a plant seed oil
produced by the recombinant camelina plant or cell of the sixth aspect of the present
invention.
According to a tenth aspect of the present invention there is provided a plant seed oil
wherein DHA constitutes at least 1%, preferably at least 3%, more preferably at least
5%, still more preferably at least 7%, still more preferably at least 10%, still more
preferably at least 13% or still more preferably at least 5% (mol %) of the total
amount of fatty acid present in said oil. Said oil may be produced by a recombinant
camelina plant or cell according to the sixth aspect of the present invention.
Preferably, according to this aspect of the invention the γ-linolenic (GLA) constitutes
less than 5%, more preferably less than 4.5%, still more preferably less than 4%, still
more preferably less than 3.5%, still more preferably less than 3%, still more
preferably less than 2.5%, still more preferably less than 2% (mol %) of the total fatty
acid content of said oil.
In one embodiment the DHA constitutes 5% to 20% (mol %) of the total fatty acid
content of said oil.
In another embodiment the DHA constitutes 5% to 20% (mol %) of the total fatty acid
content of said oil.
In another embodiment the DHA constitutes 10% to 20% (mol %) of the total fatty
acid content of said oil.
In another embodiment the DHA constitutes 10 to 15% (mol %) of the total fatty acid
content of said oil.
In another embodiment the DHA constitutes 10 to 13.7% (mol %) of the total fatty
acid content of said oil.
Preferably the combined percentage of DHA and EPA is at least 20% of the total fatty
acid content of said oil.
In one embodiment the combined percentage of DHA and EPA is 20 to 30% of the
total fatty acid content of said oil.
In one embodiment the combined percentage of DHA and EPA is 2 1 to 27% of the
total fatty acid content of said oil.
In one embodiment the DHA constitutes 4% to 10%, preferably 4% to 8%, preferably
5% to 7.5% (mol %) of the total fatty acid content of said oil.
In one embodiment the GLA constitutes 0% to 4.5% (mol %) of the total fatty acid
content of said oil.
In one embodiment the GLA constitutes 0.5% to 4.5% (mol %) of the total fatty acid
content of said oil.
In another embodiment the GLA constitutes 1.0% to 4.5% (mol %) of the total fatty
acid content of said oil.
In another embodiment the GLA constitutes 1.5% to 4.5% (mol %) of the total fatty
acid content of said oil.
In another embodiment the GLA constitutes 0% to 3.5% (mol %) of the total fatty acid
content of said oil.
In another embodiment the GLA constitutes 0.5% to 3.5% (mol %) of the total fatty
acid content of said oil.
In another embodiment the GLA constitutes 1.0% to 3.5% (mol %) of the total fatty
acid content of said oil.
In another embodiment the GLA constitutes 1.5% to 3.5% (mol %) of the total fatty
acid content of said oil.
In one embodiment the GLA constitutes 1.5% to 3.2% (mol %) of the total fatty acid
content of said oil.
The ratio of the molar percentages of EPA to DHA may be, for example, about 0.8:1
to about 1.4:1 , preferably about 1:1 to about 1:1 .3.
In another embodiment the ratio of the molar percentages of the sum of (EPA +
DHA) to GLA is about 20: 1 to about 3:1, 5 :1, 7 : or 10:1.
In another embodiment the ratio of the molar percentages of the sum of (EPA +
DHA) to GLA is about 17:1 to about 3:1, 5:1, 7:1 or 10:1.
In another embodiment the ratio of the molar percentages of the sum of (EPA +
DHA) to GLA is about 16.4:1 to about 3:1, 5:1, 7:1 or 10:1.
In another embodiment the ratio of the molar percentages of the sum of (EPA +
DHA) to GLA is about 8:1 to about 3:1 .
According to an eleventh aspect of the present invention there is provided use of
camelina in the manufacture of an omega-3 fatty acid, preferably EPA or DHA.
According to a twelfth aspect of the present invention there is provided a camelina
seed comprising a phosphatidylcholine wherein the total number of carbon atoms of
the fatty acid acyl groups of said phosphatidylcholine is 40. Preferably the seed is a
seed of the plant of the first aspect of the invention.
According to a thirteenth aspect of the present invention there is provided a camelina
seed comprising phosphatidylcholine, wherein the total number of carbon
atoms:double bonds of the fatty acid acyl groups of said phosphatidylcholine species
is selected from the group consisting of: 34:4, 34:0, 36:7, 38:1 1, 38:9, 38:8, 38:7,
38:6, 38:5, 40:1 1, 40:10, 40:9, 40:8, 40:7, 40:6, 40:5 and 40:4. Preferably the seed
comprises all the phosphatidylcholine species 34:4, 34:0, 36:7, 38:1 1, 38:9, 38:8,
38:7, 38:6, 38:5, 40:1 1, 40:10, 40:9, 40:8, 40:7, 40:6, 40:5 and 40:4. Preferably the
seed is a seed of the plant of the first aspect of the invention.
According to a fourteenth aspect of the present invention there is provided a
camelina seed comprising one or more phosphatidylethanolamine species wherein
the total number of carbon atoms:double bonds of the fatty acid acyl groups of said
phosphatidylethanolamine species is selected from the group consisting of 34:4,
36:7, 38:8, 38:7, 38:6, 38:5, 40:10, 40:9, 40:8, 40:7, 40:6, 40:5. Preferably the seed
comprises all of the phosphatidylethanolamine species 34:4, 36:7, 38:8, 38:7, 38:6,
38:5, 40:10, 40:9, 40:8, 40:7, 40:6, 40:5. Preferably the seed is a seed of the plant of
the first aspect of the invention.
According to a fifteenth aspect of the present invention there is provided a camelina
seed oil comprising the phosphatidylcholine species 34:4, 34:0, 36:7, 38:1 1, 38:9,
38:8, 38:7, 38:6, 38:5, 40:1 1, 40:10, 40:9, 40:8, 40:7, 40:6, 40:5 and 40:4. Preferably
the seed is a seed of the plant of the sixth aspect of the invention.
According to a sixteenth aspect of the present invention there is provided a camelina
seed wherein the seed comprises one or more phosphatidylethanolamine species
wherein the total number of carbon atoms:double bonds of the fatty acid acyl groups
of said phosphatidylethanolamine species is selected from the group consisting of
34:4, 36:7, 38:8, 38:7, 38:6, 38:5, 40:10, 40:9, 40:8, 40:7, 40:6, 40:5. Preferably the
camelina oil comprises all of the phosphatidylethanolamine species 34:4, 36:7, 38:8,
38:7, 38:6, 38:5, 40:10, 40:9, 40:8, 40:7, 40:6, 40:5. Preferably the seed is a seed of
the plant of the sixth aspect of the invention.
According to a seventeenth aspect of the present invention there is provided a
camelina seed or oil wherein said seed or oil comprises triglycerides wherein the
number of carbon atom double bonds of said triglycerides is 58:8, 58:9 and 58:10.
The seed or oil may be derived from the transgenic camelina plant of the invention.
In addition to the specific elongase and desaturase enzymes referred to herein, the
recombinant camelina plant or cell defined herein may further encode other enzymes
involved in polyunsaturated fatty acid synthesis, in particular enzymes involved in
omega-3 polyunsaturated fatty acid synthesis. Alternatively, the recombinant
camelina plant may only be transformed with the fatty acid synthesis enzymes
referred to herein.
The recombinant camelina plant defined herein may be in the form of a seed.
The desaturase and elongase enzymes used in the present invention may be derived
from, for example, algae, bacteria, mould or yeast.
In one embodiment, the A6-desaturase used in the present invention is derived from
Ostreococcus, preferably OtD6 from Ostreococcus tauri (Domergue et al. Biochem.
J. 389 (PT 2), 483-490 (2005). In one embodiment, the A6-desaturase is encoded by
a polynucleotide sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or
100% identity to SEQ D NO:1. In another embodiment, the A6-desaturase
comprises an amino acid sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97,
99% or 100% identity to SEQ D NO:2.
In another embodiment, the A6-desaturase used in the present invention is O809D6
from Ostreococcus RCC809. In one embodiment, the A6-desaturase is encoded by a
polynucleotide sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or
100% identity to SEQ ID NO:19. In another embodiment, the A6-desaturase
comprises an amino acid sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97,
99% or 100% identity to SEQ ID NO:20.
In one embodiment, the ∆δ-elongase used in the present invention is derived from
Physcomitrella, and is preferably from Physcomitrella patens. Preferably the ∆6-
elongase is PSE1 derived from Physcomitrella patens (Zank.et al., Plant J. 3 1 (3),
255-268 (2002); AB23891 4). In one embodiment, the A6-elongase is encoded by a
polynucleotide sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or
100% identity to SEQ ID NO:3. In another embodiment, the A6-elongase comprises
an amino acid sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or
100% identity to SEQ ID NO:4.
In another embodiment, the ∆ -elongase used in the present invention is FcElo6, a
∆6 fatty acid elongase from Fragilariopsis cylindrus CCMP 1102. In one
embodiment, the ∆δ-elongase is encoded by a polynucleotide sequence that has at
least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to SEQ ID NO:21. In
another embodiment, the ∆δ-elongase comprises an amino acid sequence that has
at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to SEQ ID NO:22.
In another embodiment, the A6-elongase used in the present invention is CeElo6, a
∆6 fatty acid elongase from Caenorhabditis elegans (Beaudoin et al., 2000, Proc Natl
Acad Sci U S A . 2000 Jun 6;97(12):6421-6). In one embodiment, the A6-elongase is
encoded by a polynucleotide sequence that has at least 50, 60, 70, 80, 85, 90, 95,
97, 99% or 100% identity to SEQ ID NO:23. In another embodiment, the ∆6-
elongase comprises an amino acid sequence that has at least 50, 60, 70, 80, 85, 90,
95, 97, 99% or 100% identity to SEQ D NO:24.
In one embodiment, the A5-desaturase used in the present invention is derived from
Thraustochytrium sp. Preferably the ∆ -desaturase is Τ ∆5 derived from
Thraustochytrium sp. (Qiu et al. J Biol Chem. 2001 Aug 24;276(34):31 561-6;
AF489588). In one embodiment, the ∆ -desaturase is encoded by a polynucleotide
sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to
SEQ ID NO:5. In another embodiment, the ∆ -desaturase comprises an amino acid
sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to
SEQ ID NO:6.
In another embodiment, the EMoD5 ∆ -desaturase from E. huxleyi (Sequence ID 9 ,
10) can be used. In one embodiment, the ∆ -desaturase is encoded by a
polynucleotide sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or
100% identity to SEQ ID NO:9. In another embodiment, the ∆ -desaturase
comprises an amino acid sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97,
99% or 100% identity to SEQ ID NO: 10.
In one embodiment, the A5-elongase used in the present invention is derived from
Ostreococcus, preferably Ostreococcus tauri. Preferably the A5-elongase is OtElo5
derived from Ostreococcus tauri (WO 20050 12316-A2; CS020 123) . n one
embodiment, the A5-elongase is encoded by a polynucleotide sequence that has at
least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to SEQ ID NO:7. In
another embodiment, the ∆ -elongase comprises an amino acid sequence that has
at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to SEQ ID NO:8.
In one embodiment, the A4-desaturase is derived from Thraustochytrium sp
(ATCC21685). In one embodiment, the A4-desaturase is encoded by a
polynucleotide sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or
100% identity to SEQ ID NO:17. In another embodiment, the A4-desaturase
comprises an amino acid sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97,
99% or 100% identity to SEQ D NO: 18.
In another embodiment the A4-desaturase is EhD4 derived from Emiliana huxleyi
(WO 20091 331 45-A1; HC086723; et al. Phytochemistry. 201 May; 72(7) .594-600).
In one embodiment, the A4-desaturase is encoded by a polynucleotide sequence
that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 00% identity to SEQ ID 15.
In another embodiment, the A4-desaturase comprises an amino acid sequence that
has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to SEQ ID NO: 16.
In another embodiment the A4-desaturase is TpDesk, a A4-desaturase from
Thalassiosira pseudonana (Tonon et al, 2005 FEBS J. 2005 Jul;272(13):3401-12). In
one embodiment, the A4-desaturase is encoded by a polynucleotide sequence that
has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to SEQ D 25. In
another embodiment, the A4-desaturase comprises an amino acid sequence that has
at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 00% identity to SEQ ID NO:26.
In one embodiment, the A12-desaturase used in the present invention is derived from
Phytophthora, and is preferably PsA12 from Phytophthora sojae (WO 2006100241
A2; CS423998). In one embodiment, the A12-desaturase is encoded by a
polynucleotide sequence that has at least 70, 80, 85, 90, 95, 97, 99% or 100%
identity to SEQ ID NO:1 1. In another embodiment, the A12-desaturase comprises an
amino acid sequence that has at least 70, 80, 85, 90, 95, 97, 99% or 100% identity to
SEQ ID NO:12.
In a one embodiment, the ω3-desaturase used in the present invention is derived
from phytophthora, preferably phytophthora infestans. Preferably the ω3-desaturase
is ρi(ω3) derived from phytophthora infestans (JP 2007527716; DJ418322). In one
embodiment, the ω3-desaturase is encoded by a polynucleotide sequence that has
at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to SEQ D NO:13. In
another embodiment, the ω3-desaturase comprises an amino acid sequence that
has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to SEQ D NO: 14.
In another embodiment, the ω3-desaturase used in the present invention is Hpw-3, a
ω3 desaturase gene from Hyaloperonospora parasitica. In one embodiment, the ω3-
desaturase is encoded by a polynucleotide sequence that has at least 50, 60, 70, 80,
85, 90, 95, 97, 99% or 100% identity to SEQ ID NO:27. In another embodiment, the
ω3-desaturase comprises an amino acid sequence that has at least 50, 60, 70, 80,
85, 90, 95, 97, 99% or 100% identity to SEQ ID NO:28.
Preferably the camelina referred to herein is Camelina satrva.
In one embodiment, the plant seed oil described herein comprises triglycerides
wherein the number of carbon atoms:double bonds of said triglycerides is 58:8, 58:9
and 58:10.
Detailed description
Various preferred features and embodiments of the present invention will now be
described by way of non-limiting examples.
The practice of the present invention will employ, unless otherwise indicated,
conventional techniques of chemistry, molecular biology, microbiology, recombinant
DNA and immunology, which are within the capabilities of a person of ordinary skill in
the art. Such techniques are explained in the literature. See, for example, J.
Sambrook, E. F. Fritsch, and T. Maniatis, 1989, Molecular Cloning: A Laboratory
Manual, Second Edition, Books 1-3, Cold Spring Harbor Laboratory Press; Ausubel,
F. M. et al. ( 1995 and periodic supplements; Current Protocols in Molecular Biology,
ch. 9, 13, and 16, John Wiley & Sons, New York, N.Y.); B. Roe, J. Crabtree, and A .
Kahn, 1996, DNA Isolation and Sequencing: Essential Techniques, John Wiley &
Sons; J. M. Polak and James O'D. McGee, 1990, In Situ Hybridization: Principles
and Practice; Oxford University Press; M. J. Gait (Editor), 1984, Oligonucleotide
Synthesis: A Practical Approach, Irl Press; D. M. J. Lilley and J. E. Dahlberg, 1992,
Methods of Enzymology: DNA Structure Part A: Synthesis and Physical Analysis of
DNA Methods in Enzymology, Academic Press; and E. M. Shevach and W . Strober,
1992 and periodic supplements, Current Protocols in Immunology, John Wiley &
Sons, New York, NY. Each of these general texts is herein incorporated by
reference.
Camelina
Camelina is a genus within the flowering plant family Brassicaceae. Camelina is an
emerging biofuel crop, in particular Camelina sativa. It is also known by other names
such as German sesame, false-flax, gold-of-pleasure, and Siberian oilseed.
Renewed interest in C. sativa as a biofuel feedstock is due in part to its drought
tolerance and minimal requirements for supplemental nitrogen and other agricultural
inputs (Gehringer et al. (2006) Genome 49(12): 1555-63; Gugel and Falk (2006)
Canadian Journal of Plant Science 86(4): 1047-1058).
Similar to other non-traditional, renewable oilseed feedstocks such as Jatropha
curcas L. ("jatropha"), C. sativa grows on marginal land. Unlike jatropha, which is a
tropical and subtropical shrub, C. sativa is native to Europe and is naturalized in
North America, where it grows well in the northern United States and southern
Canada.
In addition to its drought tolerance and broad distribution, several other aspects of C.
sativa biology make it well suited for development as an oilseed crop. First, C. sativa
is a member of the family Brassicaceae, and thus is a relative of both the genetic
model organism Arabidopsis thaliana and the common oilseed crop Brassica napus
(also known as canola). Second, the oil content of C. sativa seeds is comparable to
that of B. napus, ranging from 30 to 40% (w/w) (Budin et al. (1995). Journal of the
American Oil Chemists' Society 72(3): 309-315; Gugel and Falk (2006) Canadian
journal of plant science 86(4): 1047-1058). Finally, the properties of C. sativa
biodiesel are already well described and both seed oil and biodiesel from C. sativa
were used as fuel in engine trials with promising results (Bernardo et al. (2003)
Industrial Crops and Products 17(3): 191-197; Frohlich and Rice (2005). Industrial
Crops and Products 21(1): 25-31).
Oils, lipids and fatty acids
Polyunsaturated fatty acids can be classified into two major families (depending on
the position (n) of the first double bond nearest the methyl end of the fatty acid
carbon chain. Thus, the omega-6 fatty acids have the first unsaturated double bond
six carbon atoms from the omega (methyl) end of the molecule and additionally have
a total of two or more double bonds, with each subsequent unsaturation occurring 3
additional carbon atoms toward the carboxyl end of the molecule. In contrast, the
omega-3 fatty acids have the first unsaturated double bond three carbon atoms away
from the omega end of the molecule and additionally have a total of three or more
double bonds, with each subsequent unsaturation occurring 3 additional carbon
atoms toward the carboxyl end of the molecule.
Table 1 summarizes the common names of omega-3 fatty acids and the
abbreviations that will be used throughout the specification:
The fatty acids produced by the processes of the present invention can be isolated
from the camelina in the form of an oil, a lipid or a free fatty acid. One embodiment of
the invention is therefore oils, lipids or fatty acids or fractions thereof which have
been produced by the methods of the invention, especially preferably oil, lipid or a
fatty acid composition comprising EPA or DHA and being derived from the transgenic
camelina.
The term "oil", or "lipid" is understood as meaning a fatty acid mixture comprising
unsaturated, preferably esterified, fatty acid(s). The oil or lipid is preferably high in
omega-3 polyunstaurated or, advantageously, esterified fatty acid(s). In a particularly
preferred embodiment the oil or lipid has a high ALA, ETA, EPA, DPA and/or DHA
content, preferably a high EPA and/or DHA content.
For the analysis, the fatty acid content of the seed can, for example, be determined
by gas chromatography after converting the fatty acids into the methyl esters by
transesterification of lipids such as triacylglycerides and/or phospholipids.
The omega-3 polyunstaurated acids produced in the method of the present invention,
for example EPA and DHA, may be in the form of fatty acid derivatives, for example
sphingolipids, phosphoglycerides, lipids, glycolipids, phospholipids,
monoacylglycerol, diacylglycerol, triacylglycerol or other fatty acid esters.
The omega-3 and other polyunsaturated fatty acids which are present can be
liberated for example via treatment with alkali, for example aqueous KOH or NaOH,
or acid hydrolysis, advantageously in the presence of an alcohol such as methanol or
ethanol, or via enzymatic cleavage, and isolated via, for example, phase separation
and subsequent acidification via, for example, H2S0 4. The fatty acids can also be
liberated directly without the above-described processing step.
If further purification is necessary, standard methods can be employed. Such
methods may include extraction, treatment with urea, fractional crystallization, HPLC,
fractional distillation, silica gel chromatography, high-speed centrifugation or
distillation, or combinations of these techniques. Protection of reactive groups, such
as the acid or alkenyl groups, may be done at any step through known techniques
(e.g., alkylation, iodination, use of butylated hydroxytoluene (BHT)). Methods
used include methylation of the fatty acids to produce methyl esters. Similarly,
protecting groups may be removed at any step. Desirably, purification of fractions
containing, for example, ALA, STA, ETA, EPA, DPA and DHA may be accomplished
by treatment with urea and/or fractional distillation.
The present invention encompasses the use of the oil, lipid, the fatty acids and/or the
fatty acid composition in feedstuffs, foodstuffs, cosmetics or pharmaceuticals. The
oils, lipids, fatty acids or fatty acid mixtures according to the invention can be used in
the manner with which the skilled worker is familiar for mixing with other oils, lipids,
fatty acids or fatty acid mixtures of animal origin, such as, for example, fish oils.
Thus, the invention also provides feedstuffs, foodstuffs, cosmetics or
pharmacologicals which comprise the oils, lipids, fatty acids or fatty acid mixtures of
the present invention.
Total fatty acid content
The term "total fatty acids content" herein refers to the sum of all cellular fatty acids
that can be derivitized to fatty acid methyl esters by the base transesterification
method in a given sample (as known in the art, for example as described in
Sayanova et al., (1997) Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):421 1-6;
Sayanova et al., (2003) FEBS Lett. 2003 May 8 ;542( -3): 100-4).
Polyunsaturated fatty acid biosvnthetic genes
Microorganisms, including algae, bacteria, moulds and yeasts, can synthesize
polyunsaturated fatty acids and omega fatty acids in the ordinary course of cellular
metabolism. Particularly well-studied are fungi including Schizochytrium aggregatm,
species of the genus Thraustochytrium and Morteriella aipina. Additionally, many
dinoflagellates (Dinophyceaae) naturally produce high concentrations of
polyunsaturated fatty acids. As such, a variety of genes involved in oil production
have been identified through genetic means and the DNA sequences of some of
these genes are publicly available. Non-limiting examples are shown below:
Accession No. Description
AY1 31238 Argania spinosa ∆6 desaturase
Y0551 18 Echium pitardii var. pitardii ∆6 desaturase
AY0551 17 Echium gentianoides ∆6 desaturase
AF296076 Mucor rouxii, ∆6 desaturase
AF007561 Borago officinalis ∆6 desaturase
L 1 421 Synechocystis sp. ∆6 desaturase
NM_031344 Rattus norvegicus ∆6 fatty acid desaturase
AF465283, Mortierella aipina ∆6 fatty acid desaturase
AF465282 Mortierella isabellina ∆ 6 fatty acid desaturase
AF419296 Pythium irregulare ∆6 fatty acid desaturase
AB052086 Mucor circinelloides D6d mRNA for ∆6 fatty acid desaturase
AJ250735 Ceratodon purpureus mRNA for ∆6 fatty acid desaturase
AF 26799 Homo sapiens ∆6 fatty acid desaturase
AF1 26798 Mus musculus ∆6 fatty acid desaturase
AF1 99596, Homo sapiens ∆5 desaturase
AF320509 Rattus norvegicus liver ∆5 desaturase
AB072976 Mus musculus D5D mRNA for ∆5 desaturase
AF489588 Thraustochytrium sp. ATCC21685 ∆5 fatty acid desaturase
AJ510244 Phytophthora megasperma mRNA for ∆5 fatty acid desaturase
AF419297 Pythium irregulare ∆5 fatty acid desaturase
AF07879 Caenorhabditis elegans ∆5 fatty acid desaturase
AF067654 Mortierella alpina ∆5 fatty acid desaturase
AB022097 Dictyostelium discoideum mRNA for ∆5 fatty acid desaturase
AF489589.1 Thraustochytrium sp. ATCC21685 ∆4 fatty acid desaturase
AY332747 Pavlova lutheri ∆4 fatty acid desaturase (desl) mRNA
AAG36933 Emericella nidulans oleate ∆ 12 desaturase
AF1 10509, Mortierella alpina ∆ 12 fatty acid desaturase mRNA
AAL13300 Mortierella alpina ∆ 12 fatty acid desaturase
AF417244 Mortierella alpina ATCC 16266 ∆ 12 fatty acid desaturase
AF161219 Mucor rouxii ∆ 12 desaturase mRNA
X86736 S piruline platensis ∆ 2 desaturase
AF240777 Caenorhabditis elegans ∆ 12 desaturase
AB007640 Chlamydomonas reinhardtii ∆ 12 desaturase
AB075526 Chlorella vulgaris ∆ 12 desaturase
AP002063 Arabidopsis thaliana microsomal ∆ 12 desaturase
NP_441622, Synechocystis sp. PCC 6803 ∆ 15 desaturase
AAL36934 Perilla frutescens ∆ 15 desaturase
Additionally, the patent literature provides many additional DNA sequences of genes
(and/or details concerning several of the genes above and their methods of isolation)
involved in polyunsaturated fatty acid production. See, for example: U.S. Pat. No.
5,968,809 (∆6 desaturases); U.S. Pat. No. 5,972,664 and U.S. Pat. No. 6,075,183
(∆5 desaturases); WO 91/13972 and U.S. Pat. No. 5,057,419 (∆9 desaturases); WO
93/1 1245 (∆ 15 desaturases); WO 94/1 1516, U.S. Pat. No. 5,443,974 and WO
03/099216 (∆ 12 desaturases); U.S. 2003/0196217 A 1 (∆ 17 desaturase); WO
02/090493 (∆4 desaturases); and WO 00/12720 and U.S. 2002/01 39974A1
(elongases).
The term "desaturase" refers to a polypeptide component of a multi-enzyme complex
that can desaturate, i.e., introduce a double bond in one or more fatty acids to
produce a mono- or polyunsaturated fatty acid or precursor of interest. Some
desaturases have activity on two or more substrates. It may be desirable to
empirically determine the specificity of a fatty acid desaturase by transforming a
suitable host with the gene for the fatty acid desaturase and determining its effect on
the fatty acid profile of the host.
In the context of the present invention a 3 desaturase catalyzes the conversion of
LA to ALA (WO 2008022963-A 30 28-FEB-2008; FB753570)
In the context of the present invention a ∆6 desaturases catalyzes the conversion of
ALA to SDA and also LA to GLA. A6-Desaturases are described in WO 93/06712,
US 5,614, 393, US 5614393, WO 96/21022, W00021557 and WO 99/271 1 and their
application to production in transgenic organisms is also described, e. g . in WO
9846763, WO 9846764 and WO 9846765. In one embodiment, the A6-desaturase
used in the present invention is derived from Ostreococcus, preferably OtD6 from
Ostreococcus tauri (Domergue et al. Biochem. J. 389 (PT 2), 483-490 (2005);
AY746357). In one embodiment, the A6-desaturase is encoded by a polynucleotide
sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to
SEQ ID NO:1. In another embodiment, the ∆ -desaturase comprises an amino acid
sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to
SEQ D NO:2.
In the context of the present invention a ∆5 desaturase catalyzes the conversion of
ETA to EPA. In one embodiment, the ∆ -desaturase used in the present invention is
derived from Thraustochytrium sp. Preferably the ∆ -desaturase is Το∆5 derived
from Thraustochytrium sp. (Qiu et al. J Biol Chem. 2001 Aug 24;276(34):31561-6;
AF489588). In one embodiment, the ∆ -desaturase is encoded by a polynucleotide
sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to
SEQ ID NO:5. In another embodiment, the ∆ -desaturase comprises an amino acid
sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to
SEQ ID NO:6.
In the context of the present invention a ∆ 12 desaturases catalyzes the conversion
OA to LA. In one embodiment, the A12-desaturase used in the present invention is
Ρε∆ 12 derived from Phytophthora, preferably Phytophthora sojae (WO 2006100241
A2; CS423998). In one embodiment, the A12-desaturase is encoded by a
polynucleotide sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or
100% identity to SEQ ID NO:1 1. In another embodiment, the ∆ 12-desaturase
comprises an amino acid sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97,
99% or 100% identity to SEQ ID NO: 12.
In the context of the present invention a ∆4 desaturase catalyzes the conversion of
DPA to DHA. In one embodiment embodiment, the A4-desaturase is derived from
Thraustochytrium sp (ATCC21685). In one embodiment, the A4-desaturase is
encoded by a polynucleotide sequence that has at least 50, 60, 70, 80, 85, 90, 95,
97, 99% or 100% identity to SEQ ID NO: 17. In another embodiment, the ∆4-
desaturase comprises an amino acid sequence that has at least 50, 60, 70, 80, 85,
90, 95, 97, 99% or 100% identity to SEQ ID NO: 18.
In another embodiment the A4-desaturase is EhD4 derived from Emiliana huxleyi
(Sayanova et al. Phytochemistry. 201 1 May; 72(7):594-600). In one embodiment,
the A4-desaturase is encoded by a polynucleotide sequence that has at least 50, 60,
70, 80, 85, 90, 95, 97, 99% or 100% identity to SEQ D 15. In another embodiment,
the A4-desaturase comprises an amino acid sequence that has at least 50, 60, 70,
80, 85, 90, 95, 97, 99% or 100% identity to SEQ ID NO: 16.
The term "eiongase" refers to a polypeptide that can elongate a fatty acid carbon
chain to produce an acid two carbons longer than the fatty acid substrate that the
eiongase acts upon.
Examples of reactions catalyzed by eiongase systems are the conversion of GLA to
DGLA, SDA to ETA, ARA to DTA and EPA to DPA. In general, the substrate
selectivity of eiongases is somewhat broad but segregated by both chain length and
the degree and type of unsaturation.
For example, a C14/16 eiongase will utilize a C14 substrate (e.g., myristic acid), a
C16/18 eiongase will utilize a C16 substrate (e.g., palmitate), a C18/20 eiongase will
utilize a C18 substrate (e.g., GLA, SDA, LA, ALA) and a C20/22 eiongase (also
referred to as a ∆5 eiongase) will utilize a C20 substrate (e.g., ARA, EPA).
Since some eiongases have broad specificity, a single enzyme may be capable of
catalyzing several eiongase reactions (e.g., thereby acting as both a C16/18
eiongase and a C18/20 eiongase). It may be desirable to empirically determine the
specificity of a fatty acid eiongase by transforming a suitable host with the gene for
the fatty acid eiongase and determining its effect on the fatty acid profile of the host.
In the context of the present invention a ∆6 elongase catalyzes the conversion of
SDA to ETA. In one embodiment, the ∆6-elongase used in the present invention is
derived from Physcomitrella, and is preferably from Physcomitrella patens. Preferably
the ∆6-elongase is PSE1 derived from Physcomitrella patens (Zank,et al., Plant J. 3 1
(3), 255-268 (2002); AB238914). In one embodiment, the ∆6-elongase is encoded by
a polynucleotide sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or
100% identity to SEQ ID NO:3. In another embodiment, the ∆6-elongase comprises
an amino acid sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or
100% identity to SEQ ID NO:4.
In the context of the present invention a ∆5 elongase catalyzes the conversion of
EPA to DPA. In one embodiment, the ∆5-elongase used in the present invention is
derived from Ostreococcus, preferably Ostreococcus tauri. Preferably the ∆5-
elongase is OtElo5 derived from Ostreococcus tauri (WO 200501 231 6-A2;
CS020123). In one embodiment, the ∆5-elongase is encoded by a polynucleotide
sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to
SEQ ID NO:7. In another embodiment, the ∆5-elongase comprises an amino acid
sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to
SEQ ID NO:8.
Although the particular source of a polyunsaturated fatty acid desaturase or elongase
is not critical in the invention herein, it will be obvious to one of skill in the art that
heterologous genes will be expressed with variable efficiencies in an alternate host.
Furthermore, it may be desirable to modify the expression of particular
polyunsaturated fatty acid biosynthetic pathway enzymes to achieve optimal
conversion efficiency of each, according to the specific polyunsaturated fatty acid
product composition of interest. A variety of genetic engineering techniques are
available to optimize expression of a particular enzyme. Two such techniques include
codon optimization and gene mutation, as described below. Genes produced by e.g.,
either of these two methods, having desaturase and/or elongase activity(s) would be
useful in the invention herein for synthesis of omega-3 polyunsaturated fatty acids.
Sequence Homology or Sequence identity
"Sequence Homology or Sequence identity" is used herein interchangeably. The
terms "identical" or percent "identity" in the context of two or more nucleic acid or
protein sequences, refer to two or more sequences or subsequences that are the
same or have a specified percentage of amino acid residues or nucleotides that are
the same, when compared and aligned for maximum correspondence, as measured
using one of the following sequence comparison algorithms or by visual inspection. If
two sequences which are to be compared with each other differ in length, sequence
identity preferably relates to the percentage of the nucleotide residues of the shorter
sequence which are identical with the nucleotide residues of the longer sequence.
Sequence identity can be determined conventionally with the use of computer
programs such as the Bestfit program (Wisconsin Sequence Analysis Package,
Version 8 for Unix, Genetics Computer Group, University Research Park, 575
Science Drive Madison, Wl 5371 1). Bestfit utilizes the local homology algorithm of
Smith and Waterman, Advances in Applied Mathematics 2 (1981), 482-489, in order
to find the segment having the highest sequence identity between two sequences.
When using Bestfit or another sequence alignment program to determine whether a
particular sequence has for instance 95% identity with a reference sequence of the
present invention, the parameters are preferably so adjusted that the percentage of
identity is calculated over the entire length of the reference sequence and that
homology gaps of up to 5% of the total number of the nucleotides in the reference
sequence are permitted. When using Bestfit, the so-called optional parameters are
preferably left at their preset ("default") values. The deviations appearing in the
comparison between a given sequence and the above-described sequences of the
invention may be caused for instance by addition, deletion, substitution, insertion or
recombination. Such a sequence comparison can preferably also be carried out with
the program "fasta20u66" (version 2.0u66, September 1998 by William R. Pearson
and the University of Virginia; see also W.R. Pearson (1990), Methods in
Enzymology 183, 63-98, appended examples and http://workbench.sdsc.edu/). For
this purpose, the "default" parameter settings may be used.
Preferably, reference to a sequence which has a percent identity to any one of the
SEQ ID NOs as detailed herein refers to a sequence which has the stated percent
identity over the entire length of the SEQ ID NO referred to.
Another indication that two nucleic acid sequences are substantially identical is that
the two molecules hybridize to each other under stringent conditions.
Hybridization
Hybridization is the binding of complementary strands of DNA, D A RNA, or RNA.
Polynucleotides that hybridize to the polynucleotide sequences provided herein may also
be used in the invention. Particularly preferred are polynucleotides that hybridize under
stringent conditions to the polynucleotides described herein. As herein used, the terms
"stringent conditions" and "stringent hybridization conditions" mean hybridization occurring
only if there is at least 90%, 95% and preferably at least 97% identity between the
sequences. A specific example of stringent hybridization conditions is overnight
incubation at 42°C in a solution comprising: 50% formamide, 5x SSC (150mM NaCI,
15mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt's solution,
10% dextran sulfate, and 20 micrograms/ml of denatured, sheared salmon sperm DNA,
followed by washing the hybridization support in 0.1 x SSC at about 65°C.
The polynucleotides of the invention, may be used as a hybridization probe for RNA,
cDNA and genomic DNA to isolate other genes that have a high identity, particularly high
sequence identity.
Codon-optimization
Codon degeneracy refers to the nature in the genetic code permitting variation of the
nucleotide sequence without affecting the amino acid sequence of an encoded
polypeptide. The skilled artisan is well aware of the "codon-bias" exhibited by a
specific host cell in usage of nucleotide codons to specify a given amino acid. As will
be appreciated by one skilled in the art, it is frequently useful to modify a portion of
the codons encoding a particular polypeptide that is to be expressed in a foreign
host, such that the modified polypeptide uses codons that are preferred by the
alternate host. Use of host-preferred codons can substantially enhance the
expression of the foreign gene encoding the polypeptide.
In general, host-preferred codons can be determined within a particular host species
of interest by examining codon usage in proteins (preferably those expressed in the
largest amount) and determining which codons are used with highest frequency.
Then, the coding sequence for a polypeptide of interest having desaturase or
elongase activity can be synthesized in whole or in part using the codons preferred in
the host species. All (or portions) of the DNA also can be synthesized to remove any
destabilizing sequences or regions of secondary structure that would be present in
the transcribed mRNA. All (or portions) of the DNA also can be synthesized to alter
the base composition to one more preferable in the desired host cell.
In the present invention, it may be desirable to modify a portion of the codons
encoding the polypeptide having the relevant activity e.g., desaturase or elongase
activity, to enhance the expression of the gene in camelina.
Gene Mutation
Methods for synthesizing sequences and bringing sequences together are well
established in the literature. For example, in vitro mutagenesis and selection, site-
directed mutagenesis, error prone PGR (Melnikov et al., Nucleic Acids Research,
27(4): 1056-1 062 (Feb. 15, 1999)), "gene shuffling" or other means can be employed
to obtain mutations of naturally occurring desaturase or elongase genes. This would
permit production of a polypeptide having desaturase or elongase activity,
respectively, in vivo with more desirable physical and kinetic parameters for function
in the host cell such as a longer half-life or a higher rate of production of a desired
PUFA.
If desired, the regions of a polypeptide of interest (i.e., a desaturase or an elongase)
important for enzymatic activity can be determined through routine mutagenesis,
expression of the resulting mutant polypeptides and determination of their activities.
Mutants may include deletions, insertions and point mutations, or combinations
thereof. A typical functional analysis begins with deletion mutagenesis to determine
the N- and C-terminal limits of the protein necessary for function, and then internal
deletions, insertions or point mutants are made to further determine regions
necessary for function. Other techniques such as cassette mutagenesis or total
synthesis also can be used. Deletion mutagenesis is accomplished, for example, by
using exonucleases to sequentially remove the 5' or 3' coding regions. Kits are
available for such techniques. After deletion, the coding region is completed by
ligating oligonucleotides containing start or stop codons to the deleted coding region
after the 5' or 3' deletion, respectively. Alternatively, oligonucleotides encoding start
or stop codons are inserted into the coding region by a variety of methods including
site-directed mutagenesis, mutagenic PCR or by ligation onto DNA digested at
existing restriction sites. Internal deletions can similarly be made through a variety of
methods including the use of existing restriction sites in the DNA, by use of
mutagenic primers via site-directed mutagenesis or mutagenic PCR. Insertions are
made through methods such as linker-scanning mutagenesis, site-directed
mutagenesis or mutagenic PCR, while point mutations are made through techniques
such as site-directed mutagenesis or mutagenic PCR.
Transformation
The term "transgenic" or "recombinant" is preferably understood as meaning the
expression of the nucleic acids encoding the enzymes involved in omega-3 fatty acid
synthesis referred to herein at an unnatural locus in the genome, i.e. preferably,
heterologous expression of the nucleic acids takes place. Thus, the genes introduced
in to the camelina according to the present invention are preferably derived from a
different organism.
The polynucleotides encoding the enzymes (e.g., desaturase and elongase
enzymes) may be introduced into expression cassettes and/or vectors. In principal,
the expression cassettes can be used directly for introduction into the camelina.
However, preferably the nucleic acids are cloned into expression cassettes, which
are then used for transforming camelina with the aid of vectors such as
Agrobacterium.
After their introduction into the camelina plant cell or plant, the polynucleotides used
in the present invention can either be present on a separate plasmid or,
advantageously, integrated into the genome of the host cell.
As used in the present context, the term "vector" refers to a nucleic acid molecule
which is capable of transporting another nucleic acid to which it is bound. One type of
vector is a "plasmid", a circular double-stranded DNA loop into which additional DNA
segments can be ligated. A further type of vector is a viral vector, it being possible for
additional DNA segments to be ligated into the viral genome. Certain vectors are
capable of autonomous replication in a host cell into which they have been
introduced. Other vectors are advantageously integrated into the genome of a host
cell when they are introduced into the host cell, and thus replicate together with the
host genome. Moreover, certain vectors can govern the expression of genes with
which they are in operable linkage. These vectors are referred to in the present
context as "expression vectors". Usually, expression vectors which are suitable for
DNA recombination techniques take the form of plasmids.
The recombinant expression vectors used in the present invention are suitable for
expressing nucleic acids in a camelina host cell. The recombinant expression
vectors/polynucleotides preferably comprise one or more regulatory sequences,
which regulatory sequence(s) is/are operably linked with the nucleic acid sequence to
be expressed.
The term "operably linked" refers to the association of nucleic acid sequences on a
single nucleic acid fragment so that the function of one is affected by the other. For
example, a promoter is operably linked with a coding sequence when it is capable of
affecting the expression of that coding sequence (i.e., the coding sequence is under
the transcriptional control of the promoter). Coding sequences can be operably linked
to regulatory sequences in sense or antisense orientation.
The term "regulatory sequence" is intended to comprise promoters, enhancers and
other expression control elements such as polyadenylation signals. These regulatory
sequences are described, for example, in Goeddel: Gene Expression Technology:
Methods in Enzymology 185, Academic Press, San Diego, CA (1990), or see: Gruber
and Crosby, in: Methods in Plant Molecular Biology and Biotechnolgy, CRC Press,
Boca Raton, Florida, Ed.: Glick and Thompson, Chapter 7 , 89-108, including the
references cited therein.
Examples of plant expression vectors comprise those which are described in detail
in: Becker, D., Kemper, E., Schell, J., and Masterson, R. (1992) "New plant binary
vectors with selectable markers located proximal to the left border", Plant Mol. Biol.
20:1 195-1 197; Bevan, M.W. (1984) "Binary Agrobacterium vectors for plant
transformation", Nucl. Acids Res. 12:87 1-8721; and Vectors for Gene Transfer in
Higher Plants; in: Transgenic Plants, Vol. 1, Engineering and Utilization, Ed.: Kung
and R. Wu, Academic Press, 1993, p. 15-38.
The polynucleotide/vector preferably comprises regulatory sequences which are
capable of governing the expression of genes in plant cells and which are linked
operably so that each sequence can fulfill its function, such as transcriptional
termination, for example polyadenylation signals. Examples of polyadenylation
signals are those which are derived from Agrobacterium tumefaciens T-DNA, such as
gene 3 of the Ti plasmid pTiACH5 (Gielen et al., EMBO J. 3 (1984) 835 et seq.),
which is known as octopine synthase, or functional equivalents thereof, but other
terminator sequences which are functionally active in plants are also suitable.
Since plant gene expression is very often not limited to the transcriptional level, a
plant expression cassette or vector preferably comprises other sequences which are
linked operably, such as translation enhancers.
Plant gene expression is preferably linked operably with a suitable promoter which
triggers gene expression with the correct timing or in a cell- or tissue- specific
manner. Examples of promoters are constitutive promoters (Benfey et al., EMBO J. 8
(1989) 2195-2202), such as those which are derived from plant viruses, such as 35S
CaMV (Franck et al., Cell 2 1 (1980) 285-294), 19S Ca V (see also US 5352605 and
W O 84/02913), or plant promoters, such as the promoter of the Rubisco subunit,
which is described in US 4,962,028. Other sequences for use in operable linkage in
plant gene expression cassettes are targeting sequences, which are required for
steering the gene product into its corresponding cell compartment (see a review in
Kermode, Grit. Rev. Plant Sci. 15, 4 (1996) 285-423 and references cited therein), for
example into the vacuole, into the nucleus, all types of plastids, such as amyloplasts,
chloroplasts, chromoplasts, the extracellular space, the mitochondria, the
endoplasmid reticulum, elaioplasts, peroxisomes and other compartments of plant
cells.
Plant gene expression can also be achieved via a chemically inducible promoter (see
review in Gatz 1997, Annu. Rev. Plant Physiol. Plant Mol. Biol., 48:89-108).
Chemically inducible promoters are particularly suitable when it is desired that the
gene expression takes place in a time-specific manner. Examples of such promoters
are a salicylic acid-inducible promoter (WO 95/19443), a tetracyclin- inducible
promoter (Gatz et al. (1992) Plant J. 2, 397-404) and an ethanol-inducible promoter.
Promoters which respond to biotic or abiotic stress conditions are also suitable, for
example the pathogen-induced PRP1 gene promoter (Ward et al., Plant. Mol. Biol.
22 (1993) 361-366), the heat-inducible tomato hsp80 promoter (US 5,187,267), the
chill-inducible potato alpha-amylase promoter (WO 96/12814), the wound-inducible
pinll promoter (EP-A-0 375 091) and the cis-jasmone-responsive promoter (Matthes
MC, Bruce TJ, Ton J, Verrier PJ, Pickett JA, Napier JA. The transcriptome of cis-
jasmone-induced resistance in Arabidopsis thaliana and its role in indirect defence.
Planta. 2010 Oct;232(5): 1163-80).
Especially preferred are those promoters which bring about the gene expression in
tissues and organs in which the biosynthesis of fatty acids, lipids and oils takes
place, in seed cells, such as cells of the endosperm and of the developing embryo.
Examples of such promoters are the oilseed rape napin promoter (US 5,608,152),
the Vicia faba USP promoter (Baeumlein et al., Mol Gen Genet, 1991 , 225 (3):459-
67), the Arabidopsis oleosin promoter (WO 98/45461), the Phaseolus vulgaris
phaseolin promoter (US 5,504,200), the Brassica Bce4 promoter (WO 91/13980) or
the legumine B4 promoter (LeB4; Baeumlein et al., 1992, Plant Journal, 2 (2):233-9).
It is also envisaged that a mesocarp-specific promoter could direct the synthesis of
the omega-3 trait in oil palm and similar crops.
Other promoters are those which bring about a plastid-specific expression, since
plastids constitute the compartment in which the precursors and some end products
of lipid biosynthesis are synthesized. Examples of promoters, such as the viral RNA
polymerase promoter, are described in W O 95/16783 and WO 97/06250, and the
clpP promoter from Arabidopsis, described in WO 99/46394.
To ensure the stable integration of the biosynthesis genes into the transgenic plant
over a plurality of generations, it is usually necessary for each of the nucleic acids
which encodes a protein of interest to be expressed under the control of a separate
promoter, preferably a promoter which differs from the other promoters, since
repeating sequence motifs can lead to instability of the T-DNA, or to recombination
events. However, it is also possible to insert a plurality of nucleic acid sequences
behind a promoter and, if appropriate, before a terminator sequence. Here, the
insertion site, or the sequence, of the inserted nucleic acids in the expression
cassette is not of critical importance, that is to say a nucleic acid sequence can be
inserted at the first or last position in the cassette without its expression being
substantially influenced thereby.
Preferably, each gene introduced into the camelina plant or cell is under the control
of a specific promoter.
Vector DNA can be introduced into cells via conventional transformation or
transfection techniques. The terms "transformation" and "transfection", conjugation
and transduction, as used in the present context, are intended to comprise a
multiplicity of methods known in the prior art for the introduction of foreign nucleic
acid (for example DNA) into a host cell, including calcium phosphate or calcium
chloride coprecipitation, DEAE-dextran-mediated transfection, lipofection, natural
competence, chemically mediated transfer, electroporation or particle bombardment.
Suitable methods for the transformation or transfection of host cells, including plant
cells, can be found in Sambrook et al. (Molecular Cloning: A Laboratory Manual., 2nd
ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold
Spring Harbor, NY, 1989) and other laboratory textbooks such as Methods in
Molecular Biology, 1995, Vol. 44, Agrobacterium protocols, Ed.: Gartland and Davey,
Humana Press, Totowa, New Jersey.
Transformation systems for camelina are known in the art. For example, US
2009/0151023 describe a method which involves:
(a) Providing sterilized Camelina sativa seeds collected from a plants grown in
controlled conditions;
(b) Germinating the seeds on agar in sterilized conditions and growing in vitro
seedlings;
(c) Obtaining explants from the in vitro grown seedlings;
(d) Inoculating the explants with Agrobacterium tumefaciens strain containing at
least one recombinant DNA construct;
(e) Cocultivating the explant with the Agrobacterium strain;
(f) Transferring the explants to a callus forming medium, said medium being
supplemented with hormones and containing 2% sucrose;
(g) Transferring the explants to a shoot regeneration medium, said medium being
supplemented with hormones and containing 2-6% sucrose;
(h) Transferring the shoots to a root elongation medium, said medium being
supplemented with hormones and containing 1-4%; and
(i) Transferring the regenerated shoots into soil and growing them to transgenic
Cameiina sativa plants.
The methods for transforming cameiina disclosed in US 2009/0151028 and US
2009/0151023 are incorporated herein by reference.
Transgenic plants which comprise the polyunsaturated fatty acids synthesized in the
process according to the invention can advantageously be marketed directly without
there being any need for the oils, lipids or fatty acids synthesized to be isolated.
Plants for the process according to the invention are listed as meaning intact plants
and all plant parts, plant organs or plant parts such as leaf, stem, seeds, root, tubers,
anthers, fibers, root hairs, stalks, embryos, calli, cotelydons, petioles, harvested
material, plant tissue, reproductive tissue and cell cultures which are derived from the
actual transgenic plant and/or can be used for bringing about the transgenic plant. In
this context, the seed comprises all parts of the seed such as the seed coats,
epidermal cells, seed cells, endosperm or embryonic tissue.
The compounds produced in the process according to the invention can also be
isolated from the organisms, advantageously plants, in the form of their oils, fats,
lipids and/or free fatty acids. This can be done via pressing or extraction of the
cameiina plant parts, preferably the plant seeds. In this context, the oils, fats, lipids
and/or free fatty acids can be obtained by what is known as cold-beating or cold-
pressing without applying heat. To allow for greater ease of disruption of the plant
parts, specifically the seeds, they are previously comminuted, steamed or roasted.
The seeds which have been pretreated in this manner can subsequently be pressed
or extracted with solvents such as warm hexane. Thereafter, the resulting products
are processed further, i.e. refined. In this process, substances such as the plant
mucilages and suspended matter are first removed. What is known as desliming can
be effected enzymatically or, for example, chemico-physically by addition of acid
such as phosphoric acid. Thereafter, the free fatty acids are removed by treatment
with a base, for example sodium hydroxide solution. The resulting product is washed
thoroughly with water to remove the alkali remaining in the product and then dried.
To remove the pigment remaining in the product, the products are subjected to
bleaching, for example using filler's earth or active charcoal. At the end, the product
is deodorized, for example using steam.
Growing
In the case of plant (including plant tissue or plant organs) or plant cells, "growing" is
understood as meaning, for example, the cultivation on or in a nutrient medium, or of
the intact plant on or in a substrate, for example in a hydroponic culture, potting
compost or on arable land.
Further preferred features and embodiments of the present invention will now be
described by way of non-limiting example and with reference to the accompanying
drawings in which:
Figure 1 is a schematic showing the biosynthesis pathway for long chain
polyunsaturated fatty acids.
Figure 2 shows a schematic of the vector constructs used for Camelina
transformation.
Figure 3 shows neutral loss survey of total seed triglycerols (TAG) from wild type and
Camelina lines transformed with the five gene construct BC.
Figure 4 shows the ESI-MS analysis of wild type and Camelina lines transformed
with the five gene construct BC.
Figure 5 shows acyl composition as determined by precursor ion scanning of
phosphatidyl choline for the wild type and Camelina lines transformed with the five
gene construct BC
Figure 6 shows the distribution of acyl chains within phosphatidylcholinie of wild type
and Camelina lines transformed with the five gene construct BC.
Figure 7 shows the distribution of acyl chains within phosphatidylethanolamine of wild
type and Camelina lines transformed with the five gene construct BC.
Figure 8 shows the distribution of acyl chains within phosphatidic acid and
phosphoinositol of wild type and Camelina lines transformed with the five gene
construct BC.
Figure 9 shows the distribution of acyl chains within phosphatdylserine acid and
phosphatidylglycerol of wild type and Camelina lines transformed with the five gene
construct BC.
Figures 10 and 11 show the acyl-CoA pool of Arabidopsis and transgenic Camelina
seeds harvested at mid-stage of seed development.
Example 1 - Materials and Methods
Fatty-acid analysis
Fatty acids were extracted and methylated as described Sayanova et al., (1997) Proc
Natl Acad Sci U S A. 1997 Apr 15;94(8):421 1-6 and Sayanova et al., (2003) FEBS
Lett. 2003 May 8;542(1-3):100-4. Methyl ester derivatives of total fatty acids
extracted were analysed by GC and GC-MS. Data presented as representative
numbers derived from replicated analysis.
Acyl-CoA profiling
Twenty-milligrams of developing (15 days after flowering) seed material were
collected, frozen in liquid nitrogen and extracted after Larson and Graham 2001
(Larson TR, Graham IA. (2001), Plant J. 2001 Jan;25(1):1 15-25), for reverse-phase
LC with either quantitative analysis of fluorescent acyl-etheno-CoA derivatives or with
electrospray ionization tandem mass spectrometry (multi reaction monitoring) in
positive ion mode For the analysis of etheno-CoA derivatives HPLC (Agilent 1200 LC
system; Phenomenex LUNA 150 - 2 mm C18(2) column) was performed using the
methodology and gradient conditions described previously (Larson and Graham
2001); whilst LC-MS/MS +MRM analysis followed the methods described by Haynes
et al. 2008 (Agilent 1200 LC system ;Gemini C18 column, 2 mm inner diameter, 150
mm with 5 mm particles). For the purpose of identification and calibration, standard
acyl-CoA esters with acyl chain lengths from C14 to C20 were purchased from Sigma
as free acids or lithium salts.
Lipid Profiling
The molecular species of TAGs and PLs were analysed by electrospray ionisation
triple quadrupole mass spectrometry (API 4000 QTRAP; Applied Biosystems). The
molecular species of polar lipid were defined by the presence of a head-group
fragment and the mass/charge of the intact lipid ion formed by ESI (Welti et al., 2002,
J Biol Chem. 2002 Aug 30;277(35):31 994-2002. Devaiah et al., 2006,
Phytochemistry. 2006 Sep;67(1 7): 1907-24. with modifications described by Xiao et
al. 2010; Plant Cell. 2010 May;22(5): 1463-82.). Such tandem ESI-MS/MS precursor
and product ion scanning, based on head group fragment, do not determine the
individual fatty acyl species. Instead, polar lipids are identified at the level of class,
total acyl carbons, and total number of acyl carbon-carbon double bonds. Polar lipids
were quantified in comparison with a series of polar lipid internal standards.
Triacylglycerols (TAGs) measured after Krank et al. (2007, Methods Enzymol.
2007;432:1-20) were defined by the presence of one acyl fragment and the
mass/charge of the ion formed from the intact lipid (neutral loss profiling). This allows
identification of one TAG acyl species and the total acyl carbons and total number of
acyl double bonds in the other two chains. The procedure does not allow
identification of the other two fatty acids individually nor the positions (sn-1 , sn-2, or
sn-3) that individual acyl chains occupy on the glycerol. TAGs were quantified in a
manner similar to the polar lipids, including background subtraction, smoothing,
integration, isotope deconvolution and comparison of sample peaks with those of the
internal standard (using LipidView, Applied Biosystems). However, whereas polar
lipids within a class exhibit similar mass spectral response factors, the mass spectral
responses of various TAG species are variable, owing to differential ionization of
individual molecular TAG species. In the data shown herein, no response corrections
were applied to the data. The data were normalized to the internal standards tri15:0
and tri19:0.
Example 2 - Production of EPA in transgenic Camelina
We were interested in engineering the accumulation of bona fide omega-3 LC-
PUFAs normally associated with fish oils such as eicosapentaenoic acid (EPA; 20:5
∆5
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17) and docosahexaenoic acid (DHA; 22:6 '7 0'13 '16 '1 ) . To that end, a modular
reconstruction of their biosynthetic pathway (Fig 1) was undertaken in transgenic
Camelina. The heterolologous biosynthetic activities were all placed under the
regulatory control of common seed-specific promoters. In addition, given the variation
in codon-usage observed between angiosperms and marine algae, a number of
genes were resynthesised with codon-optimisation for expression in Cruciferae.
Constructs design
Four constructs containing from 3- to 7- gene cassettes were built using the
Gateway® recombination system (Invitrogen). Respective genes were inserted as
Nco\IPac\ fragments into the promoter/terminator cassettes and then moved into
pENTRY vectors (Fig 2). As shown, the simplest ( MC) construct contained a three
expression cassettes, comprising 1) a seed specific promoter (the sucrose binding
protein SB 800 promoter), Οί∆6, Ostreococcus tauri ∆ -desaturase gene
(Domergue et al. Biochem. J. 389 (PT 2), 483-490 (2005); AY746357) and CatpA,
terminator; 2) a seed specific promoter (USP1 promoter (Baumlein et al. 1991 o
Gen Genet. 1991 Mar;225(3):459-67), PSE1, a ∆6 fatty acid elongase from
Physcomitrella patens (Zank.et al., Plant J. 3 1 (3), 255-268 (2002); AB238914) and
CaMV35S terminator; 3) a seed specific promoter (Cnl, a conlininl promoter (Truksa
2003; Plant Physiol Biochem 41:141-147), TcA5, a A5-desaturase from
Thraustochytrium sp. (Qiu et al. J Biol Chem. 2001 Aug 24;276(34):31561-6) and
OCS, a terminator region of OCS, octopin synthase gene of A. tumefaciens.
The BC construct contained five- gene cassettes including the same 3 gene
cassettes as in the MC described above plus two additional gene cassettes
consisting of PsA12, a ∆12-desaturase gene from Phytophtora sojae (see above) and
Ρ ίω3, a ω3 desaturase gene from Phytophtora infestans (Wu et al., 2005 Nat
Biotechnol. 2005 Aug;23(8):1013-7) flanked by p, a BnNapin promoter and E9
terminator regions.
To build DHA- construct we combined BC construct with additional two-gene
cassettes, containing OtElo5, an Ostreococcus tauri ∆5 fatty acid elongase (Meyer et
al., J Lipid Res. 2004 Oct;45(10): 1899-909) and EhA4, a A4-desaturase from
Emiliania huxleyi (Sayanova et al. 201 1 Phytochemistry. 201 1 May;72(7):594-600)
flanked by napin promoters and OCS terminators.
Synthesis of EPA in transgenic Camelina
In a first iteration, the simplest 3-gene construct (MC) was introduced into transgenic
Camelina using standard floral infiltration technique to infect inflorescences with
Agrobacterium tumefaciens strains carrying binary transformation vectors. Table 2
exemplifies the accumulation of non-native omega-3 long chain polyunsaturated fatty
acids such as eicosapentaenoic acid (EPA). Total fatty acid composition of seeds
from wild-type and transgenic plants of C.sativa lines expressing MC construct are
shown below, confirming the presence of EPA in transgenics in the range 12.9-
17.3% of total seed fatty acids. Note the complete absence of this fatty acid from the
wildtype non-transgenic control.
In a second iteration of engineering Camelina with the capacity to accumulate
high levels of EPA, we transformed C. Sativa with the 5-gene construct BC,
again by floral infiltration. As shown in Table 3 below, the total fatty acid
composition of T2 seeds from transgenic plants of C.sativa expressing BC
construct contains very high levels of EPA (in the range 20.0 - 30.7%).
Moreover, as shown in Table 4 below, it was also possible to obtain EPA at a
level of 30.7% EPA. This fatty acid is totally absent from WT controls.
Table 3
Targeted lipidomic analysis of transgenic Camelina accumulating EPA.
To provide further and more detailed characterisation of the Camelina plants
accumulating high levels of EPA in the seed oil, detailed analysis was carried out
using tandem mass spectrometry as detailed below. As shown in Fig 3 , neutral loss
surveys of the total seed triacylglycerols (TAG) from either WT or two high EPA lines
(162, 26 - cf Table 3) confirmed the presence of EPA in TAGs from lines 162 and 26
and confirmed the complete absence of this fatty acid in WT seed oil. To further
define the composition of the TAGs present in the high EPA lines, ESI-MS was used
identify their molecular composition, compared with WT. As shown in Fig 4, several
novel TAG species are clearly present in lines 162 and 26 which are not present in
WT, notably 58:8, 58:9 and 58:10. Given that the predominant TAG species in WT
are 54:5-8, this upward shift represents the accumulation of longer chain fatty acids
containing additional double bonds - i.e. EPA is accumulating at 1 (or possibly 2)
positions on the glycerol backbone of TAG.
As a corollary to the analysis of neutral lipids in these Camelina lines, we also
analysed the acyi composition of phospholipids. Using precursor ion scanning, the
acyl composition of phosphatidylcholine (PC, the major phospholipid present in plant
seeds) was determined for WT and lines 162 and 26 (Fig 5). Again major differences
were identified between the WT and the high EPA transgenics, including the
identification of a series of C38 and C40 lipids were essentially absent from WT.
This alteration to the composition of phospholipids resulting from the transgenic
synthesis and accumulation of EPA was further investigated by more detailed
profiling of individual phospholipid classes (Figs 6-9). As seen in Fig 6 , this analysis
confirmed the presence of a suite of novel PC species, arising from the incorporation
of EPA into this phospholipid. It is also clear that a number of endogenous PC
species are reduced as a consequence of this accumulation, most notably the
reduction in C36 PC species containing 1-4 double bonds. A very similar profile was
observed for phosphatidylethanolamine (PE) (Fig 8), which also showed the
accumulation of novel C38 and C40 polyunsaturated species, with a concomitant
reduction in the levels of C36 PE species. We profiled the other, more minor,
phospholipid species (phosphatidic acid [PA], phosphoinositol [PI], phosphatidyserine
[PS] and phosphatidyl lycerol [PG]) and observed some more prenounced
perturbations. For example, overall levels of all PA species were increased in the
transgenic lines, albeit from a very low baseline (Fig 8). Conversely many C34 and
C36 PI species were decreased in the high EPA transgenics, though these lines did
also contain some novel C38 PUFA-containing species (Fig 8). Interestingly, PS,
which normally accumulates di + monounsaturated C20+ fatty acids was reduced in
the transgenic lines, as were C34/36 PG species (Fig 9). No novel C38/40 PS
species could be detected in our transgenic lines, whereas novel C38 PG PUFA-
containing species were observed (Fig 9).
Acyl-CoA profiling was also used to define the composition of this key metabolic hub.
As can be seen in Figs 10 & 11, the acyl-CoA pool of transgenic Camelina seeds
harvested at mid-stage of seed development revealed the presence of significant
levels of EPA-CoA.
Example 3 - Production of DHA in transgenic Camelina
Having successfully engineered the significant accumulation of EPA in transgenic
Camelina seeds, we next attempted to direct the synthesis of DHA. Since DHA is a
metabolite of EPA (Fig 1), having sufficient levels of EPA are a prerequisite for such
manipulations. Using the construct detailed in Fig 2 , we generated transgenic
Camelina plants engineered to accumulate both EPA and DHA.
Since genotyping of the T2 generation indicated that this material was not
homozygous for the transgene, we decided to carry out half-seed analysis, in which a
portion of the seed is subject to destructive FAMes analysis, but the residual portion
containing the embryo is retained and can be used to regenerate a plant. As shown
below in Table 5 , the single (half) seed analysis indeed confirmed the presence of
transgene nulls (samples 9-1 1) as would be expected from a non-homozygous
population. However, FAMEs analysis of total seed lipids did indeed confirm the
presence of EPA and DHA, the later up to levels greater than 13% of total fatty acids.
The best line showing combined levels of EPA and DHA (C20+ omega-3 LC-PUFAs)
was at 26.3 % of total seed fatty acids. Importantly, this line contained only very low
levels of the omega-6 fatty acids ARA, GLA and DHGLA and the omega-3
biosynthetic intermediates SDA, ETA and DPA. Thus this novel Camelina oil
represents a new and valuable terrestrial source of C20+ omega-3 LC-PUFAs
normally found in aquatic environments.
Table 5 . Total fatty acid composition of T2 seeds from transgenic plants of C.sativa
best lines expressing DHA-1 construct. (Half seed analysis)
To further examine the feasibility of producing EPA and DHA in transgenic Camelina
seeds, we evaluated additional activities for this capacity - 4 examples are shown
below.
Example 4 - EPA-B4.3
To the original MC construct (Fig 2; comprising 1) a seed specific promoter (the
sucrose binding protein SBP1800 promoter), OtA6, Ostreococcus tauri ∆6-
desaturase gene (Domergue et al. Biochem. J. 389 (PT 2), 483-490 (2005);
AY746357) and CatpA, terminator; 2) a seed specific promoter (USP1 promoter
(Baumlein et al. 1991 Mol Gen Genet. 1991 Mar; 225(3) :459-67), PSE1, a ∆6 fatty
acid elongase from Physcomitrella patens (Zank.et al., Plant J. 3 1 (3), 255-268
(2002); AB238914) and CaMV35S terminator; 3) a seed specific promoter (Cnl, a
conlininl promoter (Truksa 2003; Plant Physiol Biochem 41:141-147), TcA5, a ∆5-
desaturase from Thraustochytrium sp. (Qiu et al. J Biol Chem. 2001 Aug
24;276(34):31561-6) and OCS, a terminator region of OCS, octopin synthase gene of
A . tumefaciens) we added Hpw-3, a ω3 desaturase gene from Hyaloperonospora
parasitica behind the Cnl promoter and in front of OCS, a terminator region of OCS,
octopin synthase gene of A . tumefaciens
Example s - EPA-B5.1
We varied the genes present in the original BC construct (Fig 2), such that the
PsA12, a A12-desaturase gene from Phytophtora sojae and Pi 3 , a ω3 desaturase
gene from Phytophtora infestans flanked by p, a BnNapin promoter and E9
terminator regions were retained, but the actvitites were replaced with: 1) O809d6, a
D6-desaturase from Ostreococcus RCC809, flanked by the Cnl conlininl seed-
specific promoter and OCS, a terminator region of OCS, octopin synthase gene of A.
tumefaciens 2) FcElo6, a ∆6 fatty acid elongase from Fragilariopsis cylindrus CCMP
1102, flanked by the Cnl conlininl seed-specific promoter and OCS, a terminator
region of OCS, octopin synthase gene of A. tumefaciens and 3) EmiD5, a ∆5-
desaturase from Emiliana huxleyi (Sayanova et al., 201 1, Phytochemistry 72: 594-
600) flanked by the Cnl conlininl seed-specific promoter and OCS, a terminator
region of OCS, octopin synthase gene of A tumefaciens
Example 6 - EPA-B5.2
W e varied the genes present in the original BC construct (Fig 2), such that the
PSA12 , a A12-desaturase gene from Phytophtora sojae and Ρ ω3, a ω3 desaturase
gene from Phytophtora infestans flanked by Np, a BnNapin promoter and E9
terminator regions were retained, but the actvitites were replaced with: 1) O809d6, a
D6-desaturase from Ostreococcus RCC809, flanked by the Cnl conlininl seed-
specific promoter and OCS, a terminator region of OCS, octopin synthase gene of A.
tumefaciens 2) CeElo6, a ∆6 fatty acid elongase from Caenorhabditis elegans
(Beaudoin et at., 2000, Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6421-6) flanked
by the Cnl conlininl seed-specific promoter and OCS, a terminator region of OCS,
octopin synthase gene of A. tumefaciens 3) EmiD5, a A5-desaturase from Emiliana
huxleyi (Sayanova et al., 201 1, Phytochemistry 72: 594-600) flanked by the Cnl
conlininl seed-specific promoter and OCS, a terminator region of OCS, octopin
synthase gene of A. tumefaciens
Example 4 - DHA-B7.2
To the original DHA-1 construct (Fig 2), the EhD4 D4-desaturase from Emiliana
huxleyi (Sayanova et al, 201 1) was replaced by TpDesk, a D4-desaturase from
Thalassiosira pseudonana (Tonon et al, 2005 FEBS J. 2005 Jul;272(13):3401-12),
under the same regulatory elements (Cni1, OCS).
Half-seeds of primary T 1 transgenic lines were analysed by GC-FID as decribed
earlier (Example 1 - Fatty acid analysis) and examples of the fatty acid profiles
observed are shown in Table 6 below. These data indicate that the capacity of
Camelina to produce EPA and DHA is not limited to the gene sets initially described.
All publications mentioned in the above specification are herein incorporated by
reference. Various modifications and variations of the described methods and system
of the present invention will be apparent to those skilled in the art without departing
from the scope and spirit of the present invention. Although the present invention has
been described in connection with specific preferred embodiments, it should be
understood that the invention as claimed should not be unduly limited to such specific
embodiments. Indeed, various modifications of the described modes for carrying out
the invention which are obvious to those skilled in biochemistry and biotechnology or
related fields are intended to be within the scope of the following claims.














Claims:
A recombinant camelina plant or cell comprising one or more polynucleotides
encoding a ∆ -desaturase, a A6-elongase and a A5-desaturase operably
linked with one or more regulatory sequences.
A recombinant camelina plant or cell according to claim 1 which further
comprises one or more polynucleotides encoding a A12-desaturase and/or a
3 desaturase operably linked with one or more regulatory sequences.
A recombinant camelina plant according to claim 1 or 2 wherein the plant is a
seed.
A recombinant camelina plant or cell according to any one of claims 1 to 3
wherein the desaturase and elongase enzymes are independently derived
from algae, bacteria, mould or yeast.
A recombinant camelina plant or cell according to any one of claims 1 to 3
wherein the A6-desaturase comprises an amino acid sequence having at
least 50% identity to SEQ ID NO:2 or SEQ ID NO:20, the ∆ -elongase
comprises an amino acid sequence having at least 50% identity to SEQ ID
NO:4, SEQ ID NO: 22 or SEQ ID NO:24, and the ∆ -desaturase comprises
an amino acid sequence having at least 50% identity to SEQ ID NO:6 or SEQ
ID NO: 10.
A recombinant camelina plant or cell according to any one of claims 1 to 5
wherein the ∆ -desaturase is derived from Ostreococcus tauri, the ∆6-
elongase is derived from Physcomitrella patens and the ∆ -desaturase is
derived from Thraustochytrium sp.
A method for producing eicospentaenoic acid (EPA) comprising growing a
plant or cell according to any one of claims 1 or 6 under conditions wherein
said desaturase and elongase enzymes are expressed and EPA is produced
in said plant or cell.
8. A method for producing plant seed oil comprising growing a plant or cell
according to any one of claims 1 or 6 under conditions wherein said
desaturase and elongase enzymes are expressed and a plant seed oil is
produced in said plant or cell.
9. A plant seed oil produced by the method of claim 8.
0. A plant seed oil according to claim 9 wherein EPA constitutes at least 5%, at
least 10%, at least 15%, at least 20%, at least 25% or at least 30% (mol %)
of the total fatty acid content of said oil.
11. A plant seed oil wherein the EPA constitutes at least 15% (mol %) of the total
fatty acid content of said oil, and the γ-linolenic (GLA) constitutes less than
10% (mol %) of the total fatty acid content of said oil.
12. A plant seed oil according to claim 11 wherein the EPA constitutes at least
20% (mol %) of the total fatty acid content of said oil.
13. A plant seed oil according to claim 12 wherein the EPA constitutes 20% to
3 1% (mol %) of the total fatty acid content of said oil.
14. A plant seed oil according to any one of claims 11 to 13 wherein the GLA
constitutes less than 7% (mol %) of the total fatty acid content of said oil.
15. A plant seed oil according to claim 4 wherein the GLA constitutes 1% to 6%
(mol %) by weight of the total fatty acid content of said oil.
16. A plant seed oil according to any one of claims 11 to 15 wherein the ratio of
the molar percentages of EPA to γ-linolenic (GLA) is about 3:1 to about 22:1 ,
preferably about 5:1 to about 20:1.
17. A plant seed oil according to any one of claims 11 to 16 wherein the oil is
produced by the method of claim 8.
18. A recombinant camelina plant or cell comprising one or more polynucleotides
encoding a ∆ -desaturase, a ∆ -elongase, a ∆ δ-desaturase, a ∆ -elongase
and a A4-desaturase operably linked with one or more regulatory sequences.
19. A recombinant camelina plant or cell according to claim 18 which further
comprises one or more polynucleotides encoding a A12-desaturase and/or a
ω3 desaturase operably linked with one or more regulatory sequences.
20. A recombinant camelina plant according to claim 18 or 19 wherein the plant is
a seed.
21. A recombinant camelina plant or cell according to any one of claims 18 to 20
wherein the desaturase and elongase enzymes are independently derived
from algae, bacteria, mould or yeast.
22. A recombinant camelina plant or cell according to any one of claims 18 to 2 1
wherein the ∆δ-desaturase comprises an amino acid sequence having at
least 50% identity to SEQ ID NO:2 or SEQ ID NO:20, the A6-elongase
comprises an amino acid sequence having at least 50% identity to SEQ ID
NO:4, SEQ ID NO: 22 or SEQ ID NO:24, the ∆ -desaturase comprises an
amino acid sequence having at least 50% identity to SEQ ID NO:6 or SEQ ID
NO: 10, the ∆ -elongase comprises an amino acid sequence having at least
50% identity to SEQ ID NO:8 and the A4-desaturase comprises an amino
acid sequence having at least 50% identity to SEQ ID NO:16, SEQ ID NO:
18 or SEQ ID NO:26.
23. A recombinant camelina plant or cell according to any one of claims 8 to 22
wherein the ∆ -desaturase is derived from Ostreococcus tauri, the ∆6-
elongase is derived from Physcomitrella patens, the ∆ -desaturase is derived
from Thraustochytrium sp., the ∆ -elongase is derived from Ostreococcus
tauri and the A4-desaturase is derived from Emiliana huxleyi or
Thraustochytrium sp
24. A method for producing docosahexaenoic acid (DHA) comprising growing a
plant or cell according to any one of claims 8 to 23 under conditions wherein
said desaturase and elongase enzymes are expressed and DHA is produced
in said plant or cell.
25. A method for producing EPA comprising growing a plant or cell according to
according to any one of claims 18 to 23 under conditions wherein said
desaturase and elongase enzymes are expressed and EPA is produced in
said plant.
26. A method for producing a camelina oil comprising growing a plant or cell
according to any one of claims 18 to 25 wherein said desaturase and
elongase enzymes are expressed and oil is produced in said plant or cell.
27. A plant seed oil produced by the method of claim 26.
28. A plant seed oil according to claim 27 wherein DHA constitutes at least 3%, at
least 5%,at least 7%, at least 10%, or at least 13% (mol %) of the total
amount of fatty acid present in said oil.
29. A plant seed oil wherein DHA constitutes at least 3%, at least 5%, at least
7%, at least 10%, or at least 13% (mol %) of the total fatty acid content of
said oil and the γ -linolenic (GLA) constitutes less than 5% (mol %) of the total
fatty acid content of said oil.
30. A plant seed oil according to claim 29 wherein the DHA constitutes at least
13% (mol %) of the total fatty acid content of said oil.
31. A plant seed oil according to claim 30 wherein the DHA constitutes 5% to
15%, 10% to 15% or 10% to 13.7% (mol %) of the total fatty acid content of
said oil.
32. A plant seed oil according to any one of claims 29 to 3 1 wherein the GLA
constitutes less than 3.5 % (mol %) of the total fatty acid content of said oil.
33. A plant seed oil according to any one of claims 29 to 3 1 wherein the GLA
constitutes 0.5% to 5% (mol %) of the total fatty acid content of said oil.
34. A plant seed oil according to any one of claims 29 to 3 1 wherein the GLA
constitutes 1.5% to 3.5% (mol %) of the total fatty acid content of said oil.
35. A plant seed oil according to any one of claims 29 to 34 wherein the ratio of
the percentages by weight of EPA to DHA is about 0.8:1 to about 1.4:1.
36. A plant seed oil according to any one of claims 29 to 35 wherein the ratio of
the molar percentages of the sum of (EPA + DHA) to GLA is about 20:1 to
about 3:1, or about 7 :1 to about 7 :1.
37. A plant seed oil according to any one of claims 29 to 36 wherein the oil is
produced by the method of claim 26.
38. Use of camelina in the manufacture of a long chain polyunsaturated acid.
39. Use according to claim 38 wherein the long chain polyunsaturated acid is an
omega-3 long chain polyunsaturated acid
40. Use according to claim 38 wherein the long chain polyunsaturated acid is
EPA.
4 1. Use according to claim 38 wherein the long chain polyunsaturated acid is acid
DHA.
42. A feedstuff, food, cosmetic or pharmaceutical comprising the oil as defined in
any one of claims 9 to 17 or 27 to 37.
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